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Background: One of the most significant issues surrounding next generation sequencing is the cost and the
difficulty assembling short read lengths. Targeted capture enrichment of longer fragments using single molecule
sequencing (SMS) is expected to improve both sequence assembly and base-call accuracy but, at present, there are
very few examples of successful application of these technologic advances in translational research and clinical testing.
We developed a targeted single molecule sequencing (T-SMS) panel for genes implicated in ovarian response to
controlled ovarian hyperstimulation (COH) for infertility.
Results: Target enrichment was carried out using droplet-base multiplex polymerase chain reaction (PCR) technology
(RainDance®) designed to yield amplicons averaging 1 kb fragment size from candidate 44 loci (99.8% unique base-pair
coverage). The total targeted sequence was 3.18 Mb per sample. SMS was carried out using single molecule, real-time
DNA sequencing (SMRT® Pacific Biosciences®), average raw read length = 1178 nucleotides, 5% of the amplicons >6000
nucleotides). After filtering with circular consensus (CCS) reads, the mean read length was 3200 nucleotides (97% CCS
accuracy). Primary data analyses, alignment and filtering utilized the Pacific Biosciences® SMRT portal. Secondary analysis
was conducted using the Genome Analysis Toolkit for SNP discovery l and wANNOVAR for functional analysis of variants.
Filtered functional variants 18 of 19 (94.7%) were further confirmed using conventional Sanger sequencing. CCS reads were
able to accurately detect zygosity. Coverage within GC rich regions (i.e.VEGFR; 72% GC rich) was achieved by capturing
long genomic DNA (gDNA) fragments and reading into regions that flank the capture regions. As proof of concept,
a non-synonymous LHCGR variant captured in two severe OHSS cases, and verified by conventional sequencing.
Conclusions: Combining emulsion PCR-generated 1 kb amplicons and SMRT DNA sequencing permitted greater
depth of coverage for T-SMS and facilitated easier sequence assembly. To the best of our knowledge, this is the
first report combining emulsion PCR and T-SMS for long reads using human DNA samples, and NGS panel designed
for biomarker discovery in OHSS.
Keywords: Single-molecule sequencing, Droplet-based PCR, Emulsion PCR, Next generation DNA sequencing, Ovarian
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Sequence capture enrichment strategies and single mol-
ecule sequencing (SMS) are expected to increase the rate
of gene discovery for genetically heterogeneous diseases.
There have been several recent reports on the successful
application of SMS to interrogate both viral [1-4] and
bacterial [3,5-10] genomes. At present, there are very* Correspondence: Funda.e.suer@gmail.com
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article, unless otherwise stated.few examples of successful application of these techno-
logic advances in translational research and clinical test-
ing in humans. Recently, the targeted exon sequencing
of 238 cancer gene mutations from tumor/blood samples
using the PacBio RS platform was reported indicating
that achieving longer reads with SMS was feasible in hu-
man samples [11]. In that study, target enrichment was
achieved through the generation of amplicons averaging
340 bp in length.
More than one million couples worldwide seek repro-
ductive assistance each year because of infertility [12].Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ovarian stimulation (COH) may result in potentially
fatal iatrogenic ovarian hyperstimulation syndrome (OHSS).
OHSS reported as leading cause of maternal mortality in
UK [13]. The overarching objective of this study was to
identify predictive genetic biomarkers for outcome to con-
trolled ovarian hyperstimulation (COH). Patient response to
COH is variable and likely influenced by a diverse array of
genetic (and epigenetic) factors requiring sophisticated next-
generation sequencing (NGS) techniques for elucidation. To
date, there have been no tools developed to query all regions
(including intronic and 5′ and 3′UTR flanking sequences)
of candidate genes for COH and its major iatrogenic com-
plication, ovarian hyperstimulation syndrome (OHSS). We
have developed a targeted SMS (T-SMS) panel containing
44 loci that have been implicated in either response to COH
or OHSS. Our approach utilized droplet-based emulsion
PCR for the generation of 1913 amplicons averaging 1 kb in
length for T-SMS. We report the successful development
and implementation of this novel technique and an offer
proof of concept of its utility.
Methods
Sample collection and processing
This study was approved by George Washington University
Institutional Review Board. It was open to all adult
(>18 years of age) female patients recruited previously
treated or currently seeking OHSS treatment at the
GW Fertility and IVF Center. Written informed con-
sent for participation was obtained from the partici-
pants prior to sample collection. Wet lab and dry lab
work carried out within Genetics in Medicine Research
Institute of Children’s National Medical Center. Ovar-
ian hyperstimulation syndrome, non-responders and
hyper-responders to ovarian simulation were defined
clinically based on the criteria established by Navot
[14,15]. Approximately 5 mL of blood was collected
for genetic analysis.
Total genomic DNA was extracted from 200 uL
EDTA anti-coagulated venous blood using magnetic
beads (Maxwell® 16 DNA Kit DNA Purification Kit
(Promega, US) on a fully automated system. DNA (1 uL)
quality and quantity was measured (260/280 and 260/230
ratio) using a Qubit dsDNA HS assay kit and system
(Invitrogen, US). Samples showing RNA contamination
(260/280 ratio >2) were discarded and samples with a
260/230 ratio less than one were excluded from further
processing. DNA was quantified in duplicate for each
sample and the mean value was used for further calcula-
tions. DNA integrity (1 uL) was analyzed using an E-Gel®
Agarose Gel Electrophoresis System on a 0.8% agarose gel.
Samples showing fragmentation were discarded and re-
isolated from fresh patient samples. DNA (3 mg) was son-
icated using a Covaris S220 system (Covaris, US) for 180 sto ~5 kb fragment size (20% duty cycle, 5 intensity,
200 cycles per burst).
Target gene list and primer design
The target gene list was developed from an extensive lit-
erature search. It included genes that were a) implicated
in COH response, b) associated with OHSS or c) regu-
lated gonadotropin action and/or ovarian angiogenesis.
Genes included in the target list either a) harbored vari-
ants associated with COH outcome, b) displayed differ-
ential expression (mRNA, protein) in OHSS and/or 3)
played a significant role in gonadotropin signaling or in
regulating vascular permeability in the ovary. The Gen-
omic targets were comprehensive and included intronic,
exonic, 5′ and 3′ untranslated regions (UTRs) of the target
genes. The total targeted sequence consisted of 3.18 Mb
covering 44 loci with 1X tiling (see Additional file 1). The
primer library was designed using the manufacturer’s pa-
rameters (Rain Dance Technologies, US) and all primers
were first tested with Primer3 (http://frodo.wi.mit.edu/
primer3/). The primer design pipeline performed an
exhaustive primer selection across all of the regions
submitted and generated 1951 unique amplicons (average
amplicon length ~1 kb) using 3756 primers (Tm = 55-65°C,
99.8% success rate). Repeat masking was not performed on
the input regions to the primer design pipeline. Primers
were designed to provide ~100 bp overlap between adja-
cent amplicons and avoided primer binding to SNPs and
repeat regions. There was no allele dropouts discovered in
the final design.
Droplet-Based multiplex amplification
Amplification was carried out similar to previously de-
scribed methods [16] and according to the manufacturer’s
protocol. Following amplification each PCR emulsion was
broken to release individual amplicons from the PCR
droplets and samples were purified using a MinElute col-
umn (Qiagen, US) following the manufacturer’s recom-
mended protocol. Purified amplicons were then tested on
an Agilent Bioanalyzer (Agilent, US) and Qubit (Qiagen,
US) to assure quality and quantity and confirm that the
amplicon profile matches the expected histogram profile.
Library construction and single molecule, Real-Time
sequencing (SMRT)
Amplicons (1 μg) were converted to SMRTbell™ tem-
plates using the PacBio® RS DNA Template Preparation
Kit (catalog #001-322-716), incubated for 15 min at 25°C
and further purified with a 0.6X AMPure XP clean-up
kit and eluted in 30 μl buffer. Blunt adapters were li-
gated to each amplicon to facilitate circle replication
[SMRTbell™ template sequencing] and to permit error
control by calculating the consensus (‘circular consensus
sequence’ or CCS). Exonuclease incubation was carried
Table 1 Data pipeline
Primary Analyses Q metrics SMRT standard pipeline
Secondary Analyses BLASR de novo CCS aligner
algorithm filter v1 (hg19)
BLASR de novo CCS aligner algorithm was used for SNP calling using
CCS reads. Reads were filtered by length/quality and mapped to
reference sequence (UCSC, hg19). Base quality scores were recalibrated,
and consensus Filter v1: Min Read Length bp: 50, Minimum Sub Read
Length 50
GATK Overview
Variants identified using the GATK Unified Genotyper for Bayesian diploid
and haploid SNP calling using base quality score recalibration and default
settings. Indel calling was not included in SMRT pipeline
ANNOVAR Functional annotation of variants
Data visualization Overview SMART view, UCSC Genome browser, R circos plot, Partek
Table 2 Characteristics of captured sequence
Characteristic Result
Sequence yield per run (pre filter base) 800 Mb
Sequence run per sample 2 chips
Run time 2 movies, 45 min each
Mean Accuracy 10X CCS, 97.3%
Targeted Accuracy 10 X CCS, 100%
Mean Read length 3200 nt
Mean mapped read length 900 bp
Insert size 1 kb
DNA requirements 500 ng/uL
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were extracted twice (0.6X AMPure beads) and the final
“SMRT bells” were eluted in 10 μl EB. Final quantifica-
tion was carried out on an Agilent 2100 Bioanalyzer with
1 μl of library. The amount of primer and polymerase
required for the binding reaction was determined using
the SMRT bell concentration (ng/μl) and insert size pre-
viously determined using the manufacturer-provided cal-
culator. Primers were annealed and polymerase was
bound using the DNA/Polymerase Binding Kit 1.0 (PacBio
catalog #001-359-802). The complexes were stored at
−20°C or diluted for immediate sequencing.
Sequencing mixes were diluted to the required con-
centration with the manufacturer provided dilution buf-
fer prior to loading onto 96-well plates. Sample plates
were loaded onto the instrument along with the DNA
Sequencing Kit 1.0 (catalog #001-379-044). Sequencing
was performed using PacBio SMRT sequencing technol-
ogy as previously described (4) using a SMRT Cell
8Pac. In all sequencing runs, 2 x 45 min movies were
captured for each SMRT Cell loaded with a single binding
complex.
Data analyses
The data analyses pipeline is provided in Table 1. Pri-
mary filtering analysis was first performed using the Pac-
Bio RS server prior to data being transferred to the




lysis was conducted using the Genome Analysis Toolkit
(GATK) (http://www.broadinstitute.org/gatk/) embedded
in the SMRT Portal. Output files (VCF and BAM files) were
transferred to wANNOVAR (http://wannovar.usc.edu/) for
variant (SNP) calling (relative to reference sequence
assembly; hg19). The project was registered with the
NIH bioproject database (http://www.ncbi.nlm.nih.gov/
bioproject/193545). All sequence data was made access-
ible from the NIH next generation sequence read archive
(SRA) data base (http://www.ncbi.nlm.nih.gov/Traces/sra).Sanger validation of variants
Validation of SMS variants was conducted by Sanger DNA
sequencing as previously described [17]. Primers were de-
signed using the National Center for Biotechnology Informa-
tion website (http://www.ncbi.nlm.nih.gov) and University of
Santa Cruz Genome Browser (https://genome.ucsc.edu).
Multiple sequence alignments were carried out using
ChromasPro software (Technelysium Pty Ltd). All vari-
ants were reported according to standard nomenclature.
(http://www.hgvs.org/mutnomen/)
Results and discussion
Single molecule sequencing of DNA libraries
We targeted the entire coding region (exons/introns)
and the 3′ and 5′ UTR non-coding sequences of 44 can-
didate loci covering ~3.18 Mb per sample. Our primer
design yielded 3756 primer pairs that generated 1951
amplicons that were confirmed to be 1 kb in length (not
shown). Amplicons were tiled to have an average overlap
of 100 base pairs (bp) to facilitate coverage and assembly.
For the SMS-generated raw reads the average read length
was 1178 nucleotides (nt) and ~5% were >6000 nt.
SMS (2 chips per sample) was successful in capturing
100% sequence information from 1816 out of the 1951
amplicons targeted (93.1%). After filtering for circular
consensus (CCS) reads, the mean read length was
3200 nt which was likely due to the use of a longer
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(1 kb) of the amplicons (Table 2). The mean mapped
CCS read accuracy was 97%. A small percentage (5%)
of consensus reads of were >6215 nt.
We generated average 900 bp mean mapped subreads
with a mean zero-mode waveguide (ZMW) occupancy
of 85%. In our primary design, we calculated target
coverage depth using the manufacturer’s formula (6).
Based on this, we used 2 chips per sample and SMS data
were collected in 2 x 45-min movies to attain 17X tar-
geted CCS coverage depth. These results are in agree-
ment with recent targeted sequencing studies shown toFigure 1 Read length vs. GC coverage. This is a representative example
gene) and sequence results imported as custom track in UCSC Genome Br
of the VEGFA gene (grey bars above sequence). There were a total of 42 a
overlap. B. Screen capture showing the high GC content (72%) of the VEhave higher coverage depth than exome and whole gen-
ome sequencing using different enrichment strategies
[18]. Previous work has suggested that 10X CCS cover-
age depth (or 50X single read coverage = QV50) can ac-
curately (100%) distinguish between heterozygous and
homozygous SNPs [17]. Consequently, our filtering was
set to a minimum cut-off of 10 X CCS coverage depth.
Repetitive sequences
Guanine-cytosine (GC)-rich regions of the genome pose
significant challenges for high-throughput DNA sequen-
cing. We were able to sequence 1 kb amplicons generatedof typical read length and coverage (A) of GC rich regions (VEGFA
owser. Fragments (1 kb) were tiled to cover the entire genomic region
mplicons (intragenic sequences totaled 34,268 bp) with 50–150 bp
GFA gene which was successfully 005B1:1] sequenced.
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over, we were able to align these GC-rich sequences with
similar success as non-GC-rich regions which is consist-
ent with other reports [6]. As proof of concept, Figure 1
shows tiled coverage of the VEGFA gene using total 42
amplicons (Figure 1A). VEGFA has ~72% GC content
(Figure 1B). The uniform coverage for three representative
samples aligned against the hg19 reference sequence is
provided in the circos plot in Figure 2.Figure 2 Uniform Coverage between amplicons using Droplet PCR wi
target sequences in 3 samples. Outermost blue displays target genomic se
sequence, the percentage GC content is provided in purple (scale 0–100). T
The coverage of SMS for 3 representative samples is provided in red.Confirmation of T-SMS base calls
Base-call accuracy is of great concern with next gener-
ation sequencing technologies. We have validated 19
SNPs identified by T-SMS with Sanger DNA sequencing.
For those exonic variants identified by T-SMS, 18 of 19
(94.7%) of the SNPs were verified by Sanger DNA se-
quencing. As an example, Figure 3 shows the validation
of rs12470652 in the luteinizing hormone choriogonado-
tropin receptor (LHCGR) gene. This missense variantth SMS technology. Circos plot illustrating the relative coverage of
quence with respect to chromosomal location. For each target
he bases covered for bait regions are shown in green (scale 1–1000).
Figure 3 Validation of rs12470652 identified by T-SMS. SMRT® View screenshot of secondary data analysis from SMRT® Portal (A and B).
Validation of the LHCGR rs12470652 heterozygous variant discovered using T-SMS by Sanger DNA sequencing. The figure depicts the process of
biomarker identification by SMS (A and B) and validation by conventional Sanger sequencing (C).
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and variant annotation analyses steps (Figure 3A) and
was further validated using conventional Sanger sequen-
cing (Figure 3B) and here we report it in two severe
OHSS patients.Conclusions
Targeted sequencing approaches are advantageous for
enriching variant identification, simplifying data analysis
and avoiding ethical issues surrounding incidental find-
ings. We have developed a custom protocol and data
processing pipeline for generating 1 kb amplicons by
emulsion PCR for T-SMS. Our preliminary analysis has
initially focused on coding region variants in each of our
44 candidate loci for OHSS. Although smaller amplicons
may theoretically yield more readings than larger frag-
ments, we have found that fixed/same size and longer
amplicons work effectively with droplet PCR enrichment
combined with SMS. Employing T-SMS technology hasprovided improved resolution by yielding longer reads
and sequencing many target genes in a relatively short
period of time (45 min). Moreover, T-SMS of large
amplicons had low composition bias and an error pro-
file that is orthogonal to other next generation sequen-
cing platforms that have promise for clinical diagnosis.
To the best of our knowledge, this is the first study
reporting the successful sequencing of 1 kb amplicons
utilizing droplet PCR combined with SMS technology
from human samples. These data show excellent promise
for follow-up studies with a larger number of OHSS
cases.Availability of supporting data
Supporting data is included as additional files. Project
details and Sequence Data registered and can be found
in the publicly available databases: http://www.ncbi.nlm.
nih.gov/bioproject/193545 http://www.ncbi.nlm.nih.gov/
pmc/articles/PMC2808927/.
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